WO2004089333A3 - A stable benzimidazole formulation - Google Patents

A stable benzimidazole formulation Download PDF

Info

Publication number
WO2004089333A3
WO2004089333A3 PCT/IN2004/000050 IN2004000050W WO2004089333A3 WO 2004089333 A3 WO2004089333 A3 WO 2004089333A3 IN 2004000050 W IN2004000050 W IN 2004000050W WO 2004089333 A3 WO2004089333 A3 WO 2004089333A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
stable
benzimidazole formulation
stable benzimidazole
pellets
Prior art date
Application number
PCT/IN2004/000050
Other languages
French (fr)
Other versions
WO2004089333A2 (en
Inventor
Jatin Desai
Pankaj Ramanbhai Patel
Veerababu Ramabrahammam T
Pranav Jogani
Original Assignee
Cadila Healthcare Ltd
Jatin Desai
Pankaj Ramanbhai Patel
Veerababu Ramabrahammam T
Pranav Jogani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd, Jatin Desai, Pankaj Ramanbhai Patel, Veerababu Ramabrahammam T, Pranav Jogani filed Critical Cadila Healthcare Ltd
Publication of WO2004089333A2 publication Critical patent/WO2004089333A2/en
Publication of WO2004089333A3 publication Critical patent/WO2004089333A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A stable oral pharmaceutical composition containing a Benzimidazole compound or its pharmaceutically acceptable salt wherein the active ingredient is coated with an enteric coating polymer and has no separating or protective layer in between. These pellets can be filled in to the capsules or compressed into Tablets. Further disclosed is a method for the manufacture of such a formulation, and the use of such a formulation in medicine.
PCT/IN2004/000050 2003-02-28 2004-02-26 A stable benzimidazole formulation WO2004089333A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN237/MUM/2003 2003-02-28
IN237MU2003 2003-02-28

Publications (2)

Publication Number Publication Date
WO2004089333A2 WO2004089333A2 (en) 2004-10-21
WO2004089333A3 true WO2004089333A3 (en) 2005-02-03

Family

ID=33156202

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000050 WO2004089333A2 (en) 2003-02-28 2004-02-26 A stable benzimidazole formulation

Country Status (1)

Country Link
WO (1) WO2004089333A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102824323A (en) * 2012-09-25 2012-12-19 海南中化联合制药工业股份有限公司 Rabeprazole enteric orally disintegrating tablet and preparation method thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
EP2293782B1 (en) * 2008-05-06 2015-08-12 Dexcel Pharma Technologies Ltd. Stable benzimidazole formulation
WO2010018593A2 (en) * 2008-07-03 2010-02-18 Torrent Pharmaceuticals Ltd. Gastric acid resistant benzimidazole multiple unit tablet composition
BR112013000978A2 (en) * 2010-07-22 2017-07-11 Lupin Ltd multiple unit tablet composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078284A1 (en) * 1999-06-22 2000-12-28 Dexcel Ltd. Stable benzimidazole formulation
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO2001052816A2 (en) * 2000-01-19 2001-07-26 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US6391342B1 (en) * 1998-03-20 2002-05-21 A/S Gea Farmaceutisk Fabrik Pharmaceutical formulation comprising a 2- [(2-pyridinyl) methyl] sulfinyl benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
US6428810B1 (en) * 1998-11-05 2002-08-06 Astrazeneca Ab Pharmaceutical formulation comprising omeprazole

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391342B1 (en) * 1998-03-20 2002-05-21 A/S Gea Farmaceutisk Fabrik Pharmaceutical formulation comprising a 2- [(2-pyridinyl) methyl] sulfinyl benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6428810B1 (en) * 1998-11-05 2002-08-06 Astrazeneca Ab Pharmaceutical formulation comprising omeprazole
WO2000078284A1 (en) * 1999-06-22 2000-12-28 Dexcel Ltd. Stable benzimidazole formulation
WO2001052816A2 (en) * 2000-01-19 2001-07-26 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102824323A (en) * 2012-09-25 2012-12-19 海南中化联合制药工业股份有限公司 Rabeprazole enteric orally disintegrating tablet and preparation method thereof

Also Published As

Publication number Publication date
WO2004089333A2 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
CN100490790C (en) Enteric coated omeprazole pellets capsule and the preparing method thereof
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
WO2006040779A3 (en) Controlled release gastric floating matrix formulation containing imatinib
CN104220050A (en) Composite formulation comprising multi-unit spheroidal tablet (must) encapsulated in hard capsule and method for preparing same
WO2004064815A8 (en) Oral dosage formulation
ES2168043A1 (en) Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound
TW200624126A (en) New modified release tablet formulations for proton pump inhibitors
WO2004112756A8 (en) Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
JO2555B1 (en) Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent
WO2001041770A3 (en) Nanoparticulate eplerenone compositions
WO2006123357A3 (en) Oral controlled release composition containing levetiracetam
WO2004056363A3 (en) A physically and chemically stable nicotine-containing particulate material
RU2009106681A (en) GRANULAR PHARMACEUTICAL COMPOSITIONS
WO2005007139A3 (en) Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form
WO2003066030A3 (en) Pharmaceutical tablet
WO2006011159A3 (en) Stabilized pharmaceutical composition containing rabeprazole sodium with improved bioavailability
JP2006505566A5 (en)
WO2002026210A3 (en) Proton pump inhibitor formulation
ATE246505T1 (en) PREPARATION CONTAINING CEFACLOR OR CEPHALEXIN WITH MODIFIED RELEASE MATRIX
WO2004108162A3 (en) Controlled release pharmaceutical composition
WO2002028376A3 (en) Chrono delivery formulations and method of use thereof
CY1107576T1 (en) EXTREMELY RELEASE OF WATER SOLUBLE MEDICINAL SUBSTANCES
MX2010007281A (en) Pharmaceutical compositions of amlodipine and valsartan.
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
WO2009034431A3 (en) Controlled-release dosage forms for varenicline

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase